Robert I Blum

Robert I Blum (President & CEO) sold 7,500 shares of CYTK at $82.02 via 2 scheduled transactions ($615.2K total)

President & CEO Robert I Blum executed 2 separate scheduled sales totaling 7,500 shares for $615,150.00 on 2026-07-13 under a pre-arranged 10b5-1 trading plan, reducing his non-derivative holdings from 385.3K shares to 377.8K shares (-1.9%). The transaction occurred near the 52-week high of $88.31, with current price at $81.69. This is the third scheduled sale by Blum within 13 days (prior sells on 2026-07-01 and 2026-06-15), and part of an ongoing pattern of regular 10b5-1 liquidation. His cross-ticker sell history shows a negative average 90-day return of -11.0% following his open-market sales, though his same-ticker prior trades at CYTK show mixed near-term outcomes (ranging from -10.0% to +6.4% over 30 days). The company reported $19.4M revenue in the latest quarter and a $-206.0M net loss for the full year, making fundamental profitability a material context for insider activity. Blum retains 186,745 non-qualified stock options (derivative holdings), meaning his overall economic position in the company remains substantial despite the share reduction.

CEO Robert I Blum sold 7,500 shares of CYTK at $84.92 (scheduled 10b5-1 plan)

Robert I Blum, President & CEO, sold 7,500 shares at $84.92 on 2026-07-01 as part of a pre-arranged 10b5-1 trading plan, reducing his holdings from 385.3K to 377.8K shares (-1.9%). The sale occurred near the 52-week high of $88.31, with the stock up 22.0% over the preceding 30 days and 29.6% over 90 days. Since this transaction is scheduled under a 10b5-1 plan rather than discretionary, the timing reflects a pre-set formula rather than current judgments about valuation or direction. Notably, at $19.4M quarterly revenue and negative $206.0M net income, the company remains unprofitable despite 376.6% annual revenue growth—a period of fundamental expansion but continued losses. Prior sales by Blum at this ticker show mixed 30-day outcomes (+6.4%, +5.3%, -10.0%, +5.3%) and measurable 90-day results of +14.8%, offering no clear pattern of prescience at this company.

CYTK CEO Robert I Blum sells 7,500 shares at $70.46 via 10b5-1 plan; stock down 11.0% from 52-week high.

Robert I Blum sold 7,500 shares (7.5K shares) of CYTOKINETICS INC at $70.46 on 2026-06-15, reducing holdings from 392,830 to 385,330 shares, a net change of -1.9% vs pre-transaction holdings. This sale was executed under a pre-arranged 10b5-1 trading plan, making it scheduled rather than discretionary. The current stock price of $71.38 is -11.0% from the 52-week high of $80.20, and the company remains unprofitable with a net income of $-206.0M in its latest full fiscal year, though it posted strong annual revenue growth of +376.6%. His prior trades at CYTK show mixed outcomes: two prior measurable sales produced 30-day returns of +5.3% and -10.0% respectively, with 90-day returns of +14.8% and -18.6%, providing no clear directional signal. The scheduled nature of this transaction under a 10b5-1 plan means it reflects a pre-commitment to a divestment schedule rather than a response to current market or company conditions.

CEO Robert I Blum sold 7,500 shares (7.5K shares) of CYTK at $77.21 (scheduled 10b5-1 plan)

Robert I Blum, President & CEO of Cytokinetics Inc, sold 7,500 shares (7.5K shares) worth $579,075.00 ($579.1K) on 2026-05-27 as part of a pre-arranged 10b5-1 trading plan, reducing holdings from 400,330 shares (400.3K shares) to 392,830 shares (392.8K shares). The sale occurred near the 52-week high of $80.20 (stock is -4.2% from peak), following a strong 30-day gain of +26.6% and 90-day gain of +23.4%. Because this transaction is scheduled under a 10b5-1 plan rather than discretionary, it reflects pre-determined execution rather than a current market judgment. The company is unprofitable (net income $-206.0M in latest full year) despite significant revenue growth of +376.6% year-over-year, leaving operational cash generation as a key consideration for investors monitoring executive position changes.

CEO Robert I Blum sold 7,500 shares at $77.92 via 10b5-1 plan; stock near 52-week high ($80.20)

Robert I Blum, President & CEO of Cytokinetics Inc, sold 7,500 shares for $584,400 through a pre-arranged 10b5-1 trading plan on 2026-05-14, reducing holdings to 400,330 shares. This is a scheduled, non-discretionary transaction executed near the stock's 52-week high of $80.20 (current price $78.64 is -2.0% from peak), suggesting the sale was mechanically triggered by plan parameters rather than a discretionary timing decision by the insider. While Blum's historical sell track record shows a 50.00% well-timed rate with negative average returns at 30 days (-0.2%) and 90 days (-3.4%), the 10b5-1 framework precludes inferring conviction or strategic intent from this particular transaction. Investors should note the company remains deeply unprofitable with -$206.0M net income despite exceptional 376.6% annual revenue growth, making the valuation and execution timing context less material than the mechanical nature of the trade plan.

CEO Blum sells 15,000 shares of CYTK at $40.75 under 10b5-1 plan; retains 427,629 shares

Robert I. Blum, President & CEO, sold 15,000 shares at $40.75 on 2025-03-31 for a total value of $611,250.00, reducing his holdings from 442,629 shares to 427,629 shares. This sale was executed under a pre-arranged 10b5-1 trading plan, meaning it was scheduled and not a discretionary decision. The -3.4% reduction in his holdings reflects a routine portfolio adjustment under a structured plan rather than an unplanned transaction, so no inferences about his current conviction on the stock's direction can be drawn from the timing or execution of this specific trade.

CEO Robert I Blum sold 25,000 shares of CYTK at $44.65 per 10b5-1 plan on 2025-03-17

Robert I Blum, the President & CEO, executed a sale of 25,000 shares at $44.65 on 2025-03-17, reducing his holdings from 364,181 shares to 339,181 shares (a -6.9% change). This transaction was carried out under a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. The CEO retains substantial direct ownership at 339,181 shares post-transaction, indicating continued material stake in the company. As a scheduled trade under Rule 10b5-1, the timing reflects a plan adopted in advance and is not indicative of near-term conviction or concern regarding the company's prospects.

CYTK CEO Robert Blum sells 12,648 shares at $44.38; stock down -40.2% from 52-week high of $75.05

Robert I Blum, as President & CEO, sold 12,648 shares of Cytokinetics on 2025-03-17 at $44.38, reducing his holdings to 326,533 shares (-3.7% of pre-transaction holdings). The stock is currently trading at $44.91, down -40.2% from its 52-week high of $75.05 and -2.7% over the past 30 days. At the same-ticker level, Blum has executed 5 trades at CYTK in recent months (three sales in early March 2025 and two prior sales in mid-2024), with mixed timing outcomes: his August 2024 sale resulted in a 90-day +5.1% return (poorly timed), while his July 2024 sale saw a 90-day -12.2% return (well-timed). The company is unprofitable with a -$160.5M net income on quarterly revenue of $463.0K, though it has achieved +145.3% annual revenue growth. The pattern of multiple concentrated sales from the CEO within a short window (three sales within 12 days) against a deteriorated valuation backdrop warrants attention to liquidity needs and insider confidence signals at the top of the organization.

CEO Blum sells 16,970 shares of CYTK at $43.44; stock down 42.1% from 52-week high and company unprofitable

Blum Robert I, President & CEO, sold 16,970 shares (17.0K shares) of CYTOKINETICS INC at $43.44 on 2025-03-06, reducing his holdings by 4.5% to 364,181 shares (364.2K shares). The stock is currently -42.1% from its 52-week high of $75.05 and has declined 13.8% over 30 days and 14.8% over 90 days. Across his prior same-ticker history at CYTK (5 prior trades), timing outcomes are mixed: 2 of 4 prior sells with measurable 90-day outcomes were well-timed (selling before declines), while 2 were not. The company remains unprofitable with net income of $-160,545,000.00 ($-160.5M) in its most recent full fiscal year, though annual revenue growth reached +145.3%. This sale occurs as the stock trades well below peak valuations, and the insider retains substantial holdings, but the recent weak price action and unresolved profitability questions warrant monitoring of future trading activity and quarterly results.

CEO Blum sells 25,000 CYTK shares at $43.23; stock down 41.5% from 52-week high, company unprofitable with $-160.5M net loss

Robert I Blum, President & CEO, sold 25,000 shares of CYTOKINETICS INC at $43.23 on 2025-03-05, reducing his holdings from 406,151 to 381,151 shares (a 6.2% reduction). The transaction occurs against a backdrop of significant recent price weakness: the stock is currently trading at $43.88, down 41.5% from its 52-week high of $75.05, with declines of 9.5% over the past 30 days and 12.9% over 90 days. CYTOKINETICS remains unprofitable, having reported a net loss of $-160.5M on quarterly revenue of $463,000, though annual revenue growth stands at +145.3% year-over-year. His prior five sales at CYTK show mixed timing results: only 2 of 5 were well-timed at the 90-day mark, with returns ranging from +9.2% to -3.5% in the 30-day window and -12.2% to +6.2% over 90 days. The proximity of this sale to the stock's 52-week peak in the recent past and the company's ongoing unprofitability merit investor attention to both near-term execution trends and the company's path to profitability.